ERBB2 and hepatocellular carcinoma: These data are confirmed in several clinical settings: in NSCLC patients, high levels of MET protein correspond to worse clinical outcomes and represent a primary mechanism of resistance to EGFR inhibitors [19]; MET overexpression suggests increased metastatic potential and negatively influences patient survival in hepatocellular carcinoma [20], represents a human epidermal growth factor receptor 2 (HER2) independent negative prognostic marker for node-positive breast cancer [21] and a marker of invasive behavior of CRC [22].